🎉 M&A multiples are live!
Check it out!

Chengdu Kanghua Valuation Multiples

Discover revenue and EBITDA valuation multiples for Chengdu Kanghua and similar public comparables like CSL, Imugene, and GSK India.

Chengdu Kanghua Overview

About Chengdu Kanghua

Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.


Founded

2004

HQ

China
Employees

n/a

Website

kangh.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$1.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Chengdu Kanghua Financials

Chengdu Kanghua has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Chengdu Kanghua achieved revenue of $217M and an EBITDA of $86.8M.

Chengdu Kanghua expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Chengdu Kanghua valuation multiples based on analyst estimates

Chengdu Kanghua P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $217M n/a XXX XXX XXX
Gross Profit $167M $186M XXX XXX XXX
Gross Margin 77% NaN% XXX XXX XXX
EBITDA $86.8M n/a XXX XXX XXX
EBITDA Margin 40% NaN% XXX XXX XXX
Net Profit $114M $82.4M XXX XXX XXX
Net Margin 53% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Chengdu Kanghua Stock Performance

As of April 15, 2025, Chengdu Kanghua's stock price is CNY 60 (or $8).

Chengdu Kanghua has current market cap of CNY 8.0B (or $1.1B), and EV of CNY 7.5B (or $1.0B).

See Chengdu Kanghua trading valuation data

Chengdu Kanghua Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.0B $1.1B XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Chengdu Kanghua Valuation Multiples

As of April 15, 2025, Chengdu Kanghua has market cap of $1.1B and EV of $1.0B.

Chengdu Kanghua's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Chengdu Kanghua's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Chengdu Kanghua and 10K+ public comps

Chengdu Kanghua Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.0B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chengdu Kanghua Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Chengdu Kanghua Valuation Multiples

Chengdu Kanghua's NTM/LTM revenue growth is n/a

Chengdu Kanghua's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Chengdu Kanghua's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Chengdu Kanghua's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Chengdu Kanghua and other 10K+ public comps

Chengdu Kanghua Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 28% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 16% XXX XXX XXX XXX
Opex to Revenue 55% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Chengdu Kanghua Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Chengdu Kanghua M&A and Investment Activity

Chengdu Kanghua acquired  XXX companies to date.

Last acquisition by Chengdu Kanghua was  XXXXXXXX, XXXXX XXXXX XXXXXX . Chengdu Kanghua acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Chengdu Kanghua

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Chengdu Kanghua

When was Chengdu Kanghua founded? Chengdu Kanghua was founded in 2004.
Where is Chengdu Kanghua headquartered? Chengdu Kanghua is headquartered in China.
Is Chengdu Kanghua publicy listed? Yes, Chengdu Kanghua is a public company listed on SHE.
What is the stock symbol of Chengdu Kanghua? Chengdu Kanghua trades under 300841 ticker.
When did Chengdu Kanghua go public? Chengdu Kanghua went public in 2020.
Who are competitors of Chengdu Kanghua? Similar companies to Chengdu Kanghua include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Chengdu Kanghua? Chengdu Kanghua's current market cap is $1.1B
Is Chengdu Kanghua profitable? Yes, Chengdu Kanghua is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.